time to progression


Also found in: Dictionary, Acronyms, Encyclopedia.

time to progression

,

TTP

In cancer care, the number of months after the disease is recognized or treated before the patient feels worse or experiences poor health.
Mentioned in ?
References in periodicals archive ?
Only 2 patients responded, for an overall response rate of 22%, with time to progression in the 2 responders 12 and 21 weeks (Table 2).
"It is a price that has to be paid when you see improvement in time to progression," he said.
At the American Society of Hematology 45th Annual Meeting, Favrille presented interim results from the Phase II study demonstrating that following Rituxan treatment, FavId may prolong the time to progression of the disease in study patients who were relapsed or refractory following prior chemotherapy and /or Rituxan treatment.
In addition, median time to progression (TTP) was doubled with LENVIMA compared to sorafenib: 7.4 months versus 3.7 months (HR: 0.60; 95% CI: 0.51-0.71; p<0.0001) per blinded independent imaging review based on mRECIST criteria, and 7.4 months with LENVIMA versus 3.7 months with sorafenib (HR: 0.61; 95% CI: 0.51-0.72; p<0.0001) per RECIST 1.1.
Median progression-free survival (PFS), duration of response (DoR), time to progression (TTP) and overall survival (OS) have not yet been reached after a median follow-up of 10.3 months; results will be presented at a future medical congress when updated data from an expanded cohort are available.
The median time to progression was 1.2 years for virus-negative cancers, but was not reached for virus-positive cancers.
The median time to progression to diverticulitis documented by any of the four criteria was 7.1 years.
The major study endpoint was time to progression. There was no difference in the median time to progression of patients receiving DC (5.8 months) versus patients receiving FLC (6.6 months, P=0.468).
Survival rate & PSA relapse (i.e., time to progression [TTP])
and Biogen Idec's Rituxan the drug didn't show an improvement in time to progression compared to Leukine and a placebo following Rituxan.
The median time to progression was 4.4 months for the capecitabine-alone group and 8.4 months for the combination therapy group.
"We looked at our own data, and those with an early stress, especially early trauma, have a shorter time to progression of breast cancer from diagnosis compared to women with no such history," Dr.